Literature DB >> 15921055

Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.

Michael Drummond1, Andrea Manca, Mark Sculpher.   

Abstract

OBJECTIVES: Health technology assessment (HTA) is increasingly an international activity, and HTA agencies collaborate to avoid unnecessary duplication of effort. However, the sharing of the results from HTAs raises questions about their generalizability; namely, are the results of an HTA undertaken in one country relevant to another?
METHODS: This study presents recommendations for increasing the generalizability of economic evaluations. They represent an important component of HTAs and are commonly thought to have limited generalizability.
RESULTS: Recommendations are given for studies using patient-level data (i.e., evaluations conducted alongside clinical trials) and for studies using decision analytic modeling.
CONCLUSIONS: If implemented, the recommendations would increase the value for investments in HTA.

Entities:  

Mesh:

Year:  2005        PMID: 15921055

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  79 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Potential benefits of using a toolkit developed to aid in the adaptation of HTA reports: a case study considering positron emission tomography (PET) and Hodgkin's disease.

Authors:  Sheila Turner; Neil Adams; Andrew Cook; Alison Price; Ruairidh Milne
Journal:  Health Res Policy Syst       Date:  2010-05-26

3.  The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience.

Authors:  László Gulácsi
Journal:  Eur J Health Econ       Date:  2007-06

Review 4.  Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review.

Authors:  Abedin Teimourizad; Aziz Rezapour; Saeed Sadeghian; Masih Tajdini
Journal:  Cost Eff Resour Alloc       Date:  2021-05-21

5.  Programme costing of a physical activity programme in primary prevention: should the costs of health asset assessment and participatory programme development count?

Authors:  Silke B Wolfenstetter; Bernd Schweikert; Jürgen John
Journal:  Adv Prev Med       Date:  2012-03-25

Review 6.  Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.

Authors:  Federico Augustovski; Cynthia Iglesias; Andrea Manca; Michael Drummond; Adolfo Rubinstein; Sebastián García Martí
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.

Authors:  Silke B Wolfenstetter
Journal:  Prev Sci       Date:  2011-12

8.  Bayesian modelling of healthcare resource use in multinational randomized clinical trials.

Authors:  Aline Gauthier; Andrea Manca; Susan Anton
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment.

Authors:  Teresa Liu-Ambrose; Janice J Eng; Lara A Boyd; Claudia Jacova; Jennifer C Davis; Stirling Bryan; Philip Lee; Penny Brasher; Ging-Yuek R Hsiung
Journal:  BMC Neurol       Date:  2010-02-17       Impact factor: 2.474

10.  Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units.

Authors:  Rhiannon T Edwards; Barry Hounsome; Pat Linck; Ian T Russell
Journal:  Trials       Date:  2008-11-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.